161 related articles for article (PubMed ID: 21467775)
1. [Application of the benchmark dose approach to epidemiological endpoints with clinical standards].
Murata K; Karita K; Horiguchi H; Iwata T; Hirose A
Sangyo Eiseigaku Zasshi; 2011; 53(3):67-77. PubMed ID: 21467775
[TBL] [Abstract][Full Text] [Related]
2. Does EU legislation allow the use of the Benchmark Dose (BMD) approach for risk assessment?
Brandon EF; Bulder AS; van Engelen JG; Mahieu CM; Mennes WC; Pronk ME; Rietveld AG; van de Ven BM; Ten Voorde SE; Wolterink G; Slob W; Zeilmaker MJ; Bessems JG
Regul Toxicol Pharmacol; 2013 Nov; 67(2):182-8. PubMed ID: 23871753
[TBL] [Abstract][Full Text] [Related]
3. Determination of a site-specific reference dose for methylmercury for fish-eating populations.
Shipp AM; Gentry PR; Lawrence G; Van Landingham C; Covington T; Clewell HJ; Gribben K; Crump K
Toxicol Ind Health; 2000 Nov; 16(9-10):335-438. PubMed ID: 11762928
[TBL] [Abstract][Full Text] [Related]
4. Introduction to benchmark dose methods and U.S. EPA's benchmark dose software (BMDS) version 2.1.1.
Davis JA; Gift JS; Zhao QJ
Toxicol Appl Pharmacol; 2011 Jul; 254(2):181-91. PubMed ID: 21034758
[TBL] [Abstract][Full Text] [Related]
5. The benchmark dose approach in food risk assessment: is it applicable and worthwhile?
Muri SD; Schlatter JR; Brüschweiler BJ
Food Chem Toxicol; 2009 Dec; 47(12):2906-25. PubMed ID: 19682530
[TBL] [Abstract][Full Text] [Related]
6. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
Filipsson AF; Sand S; Nilsson J; Victorin K
Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the benchmark dose for point of departure determination for a variety of chemical classes in applied regulatory settings.
Izadi H; Grundy JE; Bose R
Risk Anal; 2012 May; 32(5):830-5. PubMed ID: 22126138
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of benchmark dose methodology for non-cancer continuous-data health effects in animals due to exposures to dioxin (TCDD).
Gaylor DW; Aylward LL
Regul Toxicol Pharmacol; 2004 Aug; 40(1):9-17. PubMed ID: 15265602
[TBL] [Abstract][Full Text] [Related]
9. Benchmark dose calculation for ordered categorical responses.
Chen CC; Chen JJ
Risk Anal; 2014 Aug; 34(8):1435-47. PubMed ID: 24444309
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the lower limit of benchmark dose confidence interval with no-observed-adverse-effect level by applying four different software for tumorigenicity testing of pesticides in Japan.
Yasuhiko Y; Ishigami M; Machino S; Fujii T; Aoki M; Irie F; Kanda Y; Yoshida M
Regul Toxicol Pharmacol; 2022 Aug; 133():105201. PubMed ID: 35691450
[TBL] [Abstract][Full Text] [Related]
11. Benchmark dose modeling for epidemiological dose-response assessment using prospective cohort studies.
De Pretis F; Zhou Y; Xun P; Shao K
Risk Anal; 2024 Apr; 44(4):743-756. PubMed ID: 37496455
[TBL] [Abstract][Full Text] [Related]
12. The current state of knowledge on the use of the benchmark dose concept in risk assessment.
Sand S; Victorin K; Filipsson AF
J Appl Toxicol; 2008 May; 28(4):405-21. PubMed ID: 17879232
[TBL] [Abstract][Full Text] [Related]
13. Benchmark dose calculations for PFAS exposure based on two data sets on immunotoxic effects.
Budtz-Jørgensen E; Grandjean P
Environ Health; 2023 May; 22(1):40. PubMed ID: 37147704
[TBL] [Abstract][Full Text] [Related]
14. Considerations for application of benchmark dose modeling in radiation research: workshop highlights.
Chauhan V; Yu J; Vuong N; Haber LT; Williams A; Auerbach SS; Beaton D; Wang Y; Stainforth R; Wilkins RC; Azzam EI; Richardson RB; Khan MGM; Jadhav A; Burtt JJ; Leblanc J; Randhawa K; Tollefsen KE; Yauk CL
Int J Radiat Biol; 2023; 99(9):1320-1331. PubMed ID: 36881459
[TBL] [Abstract][Full Text] [Related]
15. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.
Zhu Y; Wang T; Jelsovsky JZ
Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711
[TBL] [Abstract][Full Text] [Related]
16. Uses of benchmark dose methodology in quantitative risk assessment.
Starr TB; Goodman JI; Hoel DG
Regul Toxicol Pharmacol; 2005 Jun; 42(1):1-2. PubMed ID: 15896437
[No Abstract] [Full Text] [Related]
17. Development of an occupational exposure limit for n-propylbromide using benchmark dose methods.
Stelljes ME; Wood RR
Regul Toxicol Pharmacol; 2004 Oct; 40(2):136-50. PubMed ID: 15450717
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of subchronic toxicity data using the benchmark dose approach.
Gephart LA; Salminen WF; Nicolich MJ; Pelekis M
Regul Toxicol Pharmacol; 2001 Feb; 33(1):37-59. PubMed ID: 11259178
[TBL] [Abstract][Full Text] [Related]
19. A benchmark dose analysis for sodium monofluoroacetate (1080) using dichotomous toxicity data.
Foronda NM; Fowles J; Smith N; Taylor M; Temple W
Regul Toxicol Pharmacol; 2007 Feb; 47(1):84-9. PubMed ID: 16965845
[TBL] [Abstract][Full Text] [Related]
20. A procedure for developing risk-based reference doses.
Gaylor DW; Kodell RL
Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):137-41. PubMed ID: 12051999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
